Summary
Antibacterial drugs account for between 3 and 25% of all prescriptions, between 6 and 21 % of the total market value of drugs in a single country, and up to 50% of the drug budget in hospitals. Bacterial infection is widely perceived as disease caused by harmful outside agents which can be isolated and tested to select the best drug for treatment. In fact, the need for any treatment and the pros and cons of different drugs are just as debatable as in any other therapeutic area. Moreover, the bacteria which make up the normal flora of the body fulfil important roles, so that the ecological implications of treatment for the individual and for society should be considered in assessing the costs and consequences of antibacterial treatment. In this review we outline the most important issues relating to the treatment of bacterial infection in the community and in the hospital, contrasting information from developed and developing countries where appropriate. We review the existing literature on economic evaluation, but in general most of the literature deals with containing the costs of antibacterial drugs in hospitals, and there are many gaps in the literature on cost—effectiveness of treatment. Consequently there are still extreme variations in medical practice which present a challenge for future evaluation. As the outcomes of antibacterial treatment are apparent in a few weeks or months, this is an ideal field for testing pharmacoeconomic methodology. The desire to overcome medical practice variation through consensus statements should be avoided. Instead we recommend wider application of decision analysis to acknowledge that choices exist for the diagnosis and treatment of bacterial infection and to gather information about the implications of these choices. Much of the existing literature would be improved by a more explicit definition of costs. Direct costs to the health services should be distinguished from non medical costs. Moreover, the analysis should consider whether savings from one budget result in costs to another health service budget, or to the patient (transfer costs). These deficiencies in cost analysis will be relatively easy to correct. Of more concern is the fact that the efficacy of much antibacterial treatment is either totally debatable, or variable, depending on factors such as the type of patient treated or the quality of delivery of treatment. Policy guidelines should be based on local data about bacteria, their susceptibility to antibacterial drugs in the laboratory and the outcomes of treatment in clinical practice. These policies will require constant review.
Similar content being viewed by others
References
Achong MR, Wood J, Theal HK, Goldberg R, Thompson DA. Changes in hospital antibiotic therapy after a quality—of—use study. Lancet 26: 1118–1121, 1977
Ada GL. Modern vaccines: the immunological principles of vaccination. Lancet 335: 523–526, 1990
Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. British Medical Journal 300: 1619–1621, 1990
Andersen TF, Mooney G. Medical practice variations: Where are we? In Anderson TF & Mooney G. (Eds) The challenges of medical practice variations, pp. 1–15, Macmillan Press, Basingstoke, Hampshire, 1990
Anderson RM, May RM. Modern vaccines: immunisation and herd immunity. Lancet 335: 641–645, 1990
Anon. Quinolones in acute non—travellers’ diarrhoea. Lancet 2: 282, 1990
Anon. Rediscovering wormwood: quinghaosu for malaria. Lancet 339: 649–651, 1992
Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 106: 196–204, 1987
Archer DL, Young FE. Contemporary issues: diseases with a food vector. Clinical Microbiology Reviews 1: 377–398, 1988
Arevalo JA, Washington AE. Cost—effectiveness of prenatal screening. Journal of the American Medical Association 259: 365–369, 1988
Avorn J, Soumerai SB, Taylor W, Wessels MR, Janousek J, et al. Reduction of incorrect antibiotic dosing through a structured educational order form. Archives of Internal Medicine 148: 1720–1724, 1988
Avorn J, Soumerai SB. Improving drug—therapy decisions through educational outreach. A randomized controlled trial of academically based,detailing,. New England Journal of Medicine 308: 1457–1463, 1983
Bailey IS, Karran SE, Toyn K, Brough P, Ranabaldo C, et al. Community surveillance of complications after hernia surgery. British Medical Journal 304: 469–471, 1992
Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. Journal of Antimicrobial Chemotherapy 28 (Suppl. c): 31–38, 1991
Barnass S, O’Mahony M, Sockett PN, Garner J, Franklin J, et al. The tangible cost implications of a hospital outbreak of multiply—resistant Salmonella. Epidemiology and Infection 103: 227–234, 1989
Barriere SL. Cost containment of antimicrobial therapy. Drug Intelligence and Clinical Pharmacy 19: 278–281, 1985
Bass JW. Treatment of streptococcal pharyngitis revisited. Journal of the American Medical Association 256: 740–743, 1986
Bass JW. The treatment of streptococcal pharyngitis. Journal of the American Medical Association 257: 187, 1987
Begley CE, Mc Gill L, Smith PE. The incremental cost of screening, diagnosis and treatment of gonorrhea and chlamydia in a family planning clinic. Sexually Transmitted Diseases 16: 63–67, 1989
Bendall MJ, Ebrahim S, Finch RG, Slack RC, Towner KJ. The effect of an antibiotic policy on bacterial resistance in patients in geriatric medical wards. Quarterly Journal of Medicine 60: 849–854, 1986
Bhopal RS, Thomson R. A form to help learn and teach about assessing medical audit papers. British Medical Journal 303: 1520–1522, 1991
Bisno AL. The resurgence of acute rheumatic fever in the United States. Annual Review of Medicine 41: 319–329, 1990
Bollag U, Bollag-Albrecht E. Recommendations derived from practice audit for the treatment of acute otitis media. Lancet 338: 96–99, 1991
Briceland LL, Nightingale CH, Quintiliani R, Cooper BW. Multidisciplinary cost—containment program promoting less frequent administration of injectable mezlocillin. American Journal of Hospital Pharmacy 45: 1082–1085, 1988
Brook I. Treatment of patients with acute recurrent tonsillitis due to group A B—haemolytic streptococci: a prospective randomized study comparing penicillin and amoxycillin/clavulanate potassium. Journal of Antimicrobial Chemotherapy 24: 227–233, 1989
Brunette MG, Lands L, Thibodeau L-G. Childhood asthma: prevention of attacks with short—term corticosteroid treatment of upper respiratory tract infection. Pediatrics 81: 624–629, 1988
Burke P, Bain J, Robinson D, Dunleavy J. Acute red ear in children: controlled trial of non—antibiotic treatment in general practice. British Medical Journal 303: 558–562, 1991
Canafax DM, Giebink GS. Clinical and pharmacokinetic basis for the antimicrobial treatment of acute otitis media. Otolaryngologic Clinics of North America 24: 859–875, 1991
Cantekin EI, Mc Guire TW, Griffith TL. Antimicrobial therapy for otitis media with effusion (‘secretory’ otitis media). Journal of the American Medical Association 266: 3309–3317, 1991
Carlson KJ. Cost—effectiveness of single—dose therapy of urinary tract infection compared to conventional treatment. European Urology 138: 45–47, 1987
Carlson KJ, Mulley AG. Management of acute dysuria: A decision analysis model of alternative stategies. Annals of Internal Medicine 102: 244–249, 1985
Cebul RD, Poses RM. The comparative cost—effectiveness of statistical decision rules and experienced physicians in pharyngitis management. Journal of the American Medical Association 256: 3353–3357, 1986
Centor RM, Witherspoon JM, Dalton HP. The diagnosis of strep throat in an emergency room. Medical Decision Making 1: 239–246, 1981
Clark CM, Bailie GR, Whitaker AM, Goldberg LA. Parenteral drug delivery: value for money? Pharmaceutical Journal 12: 453–455, 1986
Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical—wound infection. New England Journal of Medicine 326: 281–286, 1992
Clendennen TE, Hames CS, Kees ES, Price FC, Rueppel WJ, et al. Invitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrobial Agents and Chemotherapy 36: 277–282, 1992
Col NF, O’Connor RW. Estimating worldwide current antibiotic usage: report of Task Force I. Reviews ofinfectious Diseases 9 (Suppl. 3): S232–S243, 1987
Coleman RW, Rodoni LC, Kaubisch S, Granzella NB, O’Hanley PD. Cost—effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987–1989. American Journal of Medicine 90: 439–444, 1991
Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. Journal of Antimicrobial Chemotherapy 23: 441–451, 1989
Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug—monitoring program on total aminoglycoside dose and cost of hospitalization. Therapeutic Drug Monitoring 9: 306–310, 1987
Currie E, Maynard A. The economics of hospital—acquired infection. Centre for Health Economics Discussion Paper No. 56, 1989
Dagan R, Bar-David Y. Double—blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin—resistant Staphylococcus aureus strains. Antimicrobial Agents and Chemotherapy 36: 287–290, 1992
Daly KA. Epidemiology of otitis media. Otolaryngologic Clinics of North America 24: 775–786, 1991
Daschner F. Cost—effectiveness in hospital infection control: — lessons for the 1990s. Journal of Hospital Infection 13: 325–336, 1989
Daschner F. Unnecessary and ecological cost of hospital acquired infection. Journal of Hospital Infection 18 (Suppl. A): 73–78, 1991
Davey P, Duncan ID, Edward D, Scott AC. Cost—benefit—analysis of cephradine and mezlocillin prophylaxis for abdominal and vaginal hysterectomy. British Journal of Obstetrics and Gynaecology 95: 1170–1177, 1988
Davey P, Dodd T, Kerr S, Malek M. Audit ofiv antibiotic administration. Pharmaceutical Journal 30: 793–796, 1990
Davey P, Hernanz C, Lynch W, Malek M, Byrne DJ. Human and non—financial costs of hospital—acquired—infection. Journal of Hospital Infection (Suppl. A): 79–84, 1991
Davey P, Malek M. Pharmacoeconomics of antibacterial treatment. Current Opinion in Infectious Disease 3: 780–785, 1990
Davey P, Malek M. Costs of hospital acquired infection. Pharmaceutical Journal (Hospital Suppl.): HS12-HS18, 1991
Dean T. FHSA medical advisers: a survey of attitudes. Prescriber 2: 79–80, 1991
Denton M, Morgan MS, White RR. Quality of prescribing of intravenous antibiotics in a district general hospital. British Medical Journal 302: 327–328, 1991
Donaldson C, Mooney G. Needs assessment, priority setting and contracts for health care: an economic view. British Medical Journal 303: 1529–1530, 1991
Dornbusch K, Miller GH, Hare RS, Shaw KJ, ESGAR Study Group. Resistance to aminoglycoside antibiotics in Gram—negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. Journal of Antimicrobial Chemotherapy 26: 131–144, 1990a
Dornbusch K, European Study Group on Antibiotic Resistance. Resistance to B—lactam antibiotics and ciprofloxacin in Gramnegative bacilli and staphylococci isolated from blood: a European collaborative study. Journal of Antimicrobial Chemotherapy 26: 269–278, 1990b
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, 1987
Dunagan WC, Woodward RS, Medoff G, Gray JL, Casabar E, et al. Antimicrobial misuse in patients with positive blood cultures. American Journal of Medicine 87: 253–259, 1989
Du Pont HL, Ericsson CD, Mathewson JJ, Du Pont MW. Five versus three days of ofloxacin therapy for traveler’s diarrhea: a placebo—controlled study. Antimicrobial Agents and Chemotherapy 36: 87–91, 1992
Dzierba SH, Reilly RT, Caselnova DA. Cost savings achieved through cephalosporin use review and restriction. American Journal of Hospital Pharmacy 43: 2194–2197, 1986
Ehrenkranz NJ. Containing costs of antimicrobials in the hospital: a critical evaluation. American Journal oflnfection Control 17: 300–310, 1989
Endtz HP, Mouton RP, van der Reyden T, Ruijs GJ, Biever M, et al. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products. Lancet 335: 787, 1990
EPINE Working Group. Prevalence of hospital-acquired infection in Spain. Journal of Hospital Infection 20: 1–13, 1992
Fihn SD, Johnson C, Roberts PL, Running K, Stamm WE. Trimethoprim—sulfamethoxazole for acute dysuria in women: a single—dose or 10−day course. Annals oflnternal Medicine 108: 350–357, 1988
Fine PEM, Rodrigues LE. Modem vaccines: mycobacterial diseases. Lancet 335: 1016–1020, 1990
Fitzgerald D. Issues in managing innovative research for drug discovery. In Walker SR (Ed.) Creating the right environment for drug discovery, pp. 33–49, Quay, London, 1991
Franzblau SG, Biswas AN, Harris EB. Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae. Antimicrobial Agents and Chemotherapy 36: 92–94, 1992
Frater A, Costain D. Any better? Outcome measures in medical audit. British Medical Journal 304: 519–520, 1992
French GL, Cheng AFB. Measurement of the costs of hospital infection by prevalence surveys. Journal of Hospital Infection 18 (Suppl. A): 65–72, 1991
Friis H, Bro F, Mabeck CE, Vejlsgaard R. An information campaign: an important measure in controlling the use of antibiotics. Journal of Antimicrobial Chemotherapy 24: 993–999, 1989a
Friis H, Mortensen N, Pinholt H, Schmidt K, Schouenborg P, et al. Regional variation in the use of antibiotics in four Danish hospitals. Infection 17: 139–141, 1989b
Froom J, Culpepper L, Grob P, Bartelds A, Bowers P, et al. Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. British Medical Journal 300: 582–586, 1990
Fry J. Acute throat infections. Update: 1181–1183, 1979
Galanduik S, Polk HC, Jagelman DG, Fazio VW. Re—emphasis of priorities in surgical antibiotic prophylaxis. Surgery, Gynaecology and Obstetrics 169: 219–222, 1989
Gerber MA, Randolph MF, De Meo KK, Kaplan EL. Lack of impact of early antibiotic therapy for streptococcal pharyngitis on recurrence rates. Journal of Pediatrics 117: 853–858, 1990
Gluckman SJ, Di Nubile MJ. Controversial issues in the management of urinary tract infections. Current Opinions in Infectious Disease 5: 50–56, 1992
Gotuzzo E, Oberhelman RA, Maguina C, Berry SJ, Vi A, et al. Comparison of single—dose treatment with norfloxacin and standard 5−day treatment with trimethoprim—sulfamethoxazole for acute shigellosis in adults. Antimicrobial Agents and Chemotherapy 33: 1101–1104, 1989
Gould I. Control of antibiotic use in the United Kingdom. Journal of Antimicrobial Chemotherapy 22: 395–397, 1988
Grahn E, Holm SE, Roos K. Penicillin tolerance in B—streptococci isolated from patients with tonsillitis. Scandinavian Journal of Infectious Diseases 19: 421–428, 1987
Grahn E, Holm SE. Penicillin concentration in saliva and its influence on bacterial interference. Scandinavian Journal of Infectious Diseases 19: 235–241, 1987a
Grahn E, Holm SE. The effect of penicillin on bacterial interference in vivo. Scandinavian Journal of Infectious Diseases 19: 353–359, 1987b
Greene SA, Record KE, Rapp RP, Amerson AB, Bell RM, et al. Pharmacy initiatives to reduce c1indamycin use. American Journal of Hospital Pharmacy 43: 1210–1213, 1986
Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. American Journal of Medicine 91 (Suppl. 3B): 32S–38S, 1991
Hall AJ, Greenwood BM, Whittle H. Modern vaccines: practice in developing countries. Lancet 335: 774–777, 1990
Harari M, Shann F, Spooner V, Meisner S, Carney M, et al. Clinical signs of pneumonia in children. Lancet 338: 928–930, 1991
Harvey KJ, Stewart R, Hemming M, Naismith N, Moulds RFW. Educational antibiotic advertising. Medical Journal of Australia 145: 28–32, 1986
Hastings RC, Gillis TP, Krahenbuhl JL, Franzblau SG. Leprosy. Clinical Microbiology Reviews 1: 330–348, 1988
Hierholzer WJ. Health care data, the epidemiologist’s sand: comments on the Quantity and Quality of data. American Journal of Medicine 91 (Suppl. 3B): 3B–21S -3B-26S, 1991
Hinman AR, Orenstein WA. Modern vaccines: immunisation practice in developed countries. Lancet 335: 707–710, 1990
Hodson ME, Penketh ARL, Batten JE. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 2: 1137–1139, 1981
Houston S, Pozniak A, Ray CS. Therapeutics review: tuberculosis. Central Africa Journal of Medicine 37: 250–255, 1991
Howard AJ, Dunkin KT, Musser JM, Palmer SR. Epidemiology of Haemophilus influenzae type B invasive disease in Wales. British Medical Journal 303: 441–445, 1991
Howie JGR, Richardson JM, Duono D. Respiratory illness and antbiotic use in general practice. Journal of the Royal College of General Practitioners 21: 657, 1971
Hutchison BG, Stoddart GL. Cost—effectiveness of primary tetanus vaccination among elderly Canadians. Canadian Medical Association Journal 139: 1143–1151, 1988
Isenberg HD. Pathogenicity and virulence: another view. Clinical Microbiology Reviews 1: 40–53, 1988
Jewesson PJ, Bachand RL, Bell GA, Ensom RJ, Chow AW. Quality of use of parenteral metronidazole therapy in a teaching hospital. Canadian Medical Association Journal 132: 785–789, 1985
Ji B, Perani EG, Grosset JH. Effectiveness of clarithroycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrobial Agents and Chemotherapy 35: 579–581, 1991
Joesoef MR, Remindton PL, Jiptoherijanto PT. Epidemiological model and cost—effectiveness analysis of tuberculosis treatment programmes in Indonesia. International Journal of Epidemiology 18: 174–179, 1989
Juul-Jensen U. Practice and progress. A theory for the modem health care system, Blackwell, Oxford, 1987
Kaleida PH, Casselbrant ML, Rockette HE, Paradise JL, Bluestone CD, et al. Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial. Pediatrics 87: 466–474, 1991
Kayser FH, Morenzoni G, Santanam P. The second european collaborative study on the frequency of antimicrobial resistance in Haemophilus influenzae. European Journal of Clinical Microbiology and Infectious Diseases 9: 810–817, 1990
Keroack MA. Invasive group A streptococcal infection and streptococcal toxic shock syndrome. Current Opinion in Infectious Diseases 4: 621–627, 1991
Kopp DL, Hammel RJ. Justification for a pharmacy—coordinated iv therapy team. Hospital Pharmacy 13: 375–384, 1978
Kumana CR, Li KY, Kou M, Chan SC. Cephalosporin and aminoglycoside utilization in different parts of the world. Journal of Antimicrobial Chemotherapy 24: 1001–1010, 1989
Kunin C. Cost—effective use of antibiotics. Archives of Internal Medicine 148: 1709–1710, 1988
Kwan JTC, Hart PD, Raftery MJ, Cunningham J, Marsh FP. Mycobacterial infection is an important infective complication in British Asian dialysis patients. Journal of Hospital Infection 19: 249–255, 1991
Lamikanra A, Ndep RB. Trimethoprim resistance in urinary tract pathogens in two Nigerian hospitals. Journal of Antimicrobial Chemotherapy 23: 151–154, 1989
Landgren FT, Harvey KJ, Mashford ML, Moulds RFW, Guthrie B, et al. Changing antibiotic prescribing by educational marketing. Medical Journal of Australia 149: 595–599, 1988
Law DJW, Mishriki SF, Jeffrey PJ. The importance of surveillance after discharge from hospital and the diagnosis of post—operative wound infection. Annals of Royal College of Surgeons of England 72: 207–209, 1990
Lawrence VA, Gafni A, Gross M. The unproven utility of the preoperative urinalysis: economic evaluation. Journal of Clinical Epidemiology 42: 1185–1192, 1989
Levine M. Modem vaccines: enteric infections. Lancet 335: 958–961, 1990
Li SC, Ioannides-Demos W, Spicer WJ, Berbatis C, Spelman DW, et al. Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Medical Journal of Australia 151: 224–232, 1989
Linton AH. Antibiotic resistance in bacteria associated with animals and their importance to man. Journal of Antimicrobial Chemotherapy 15: 385–386, 1985
Liss RH, Batchelor FR. Economic evaluations of antibiotic use and resistance: a perspective report of Task Force 6. Reviews of infectious Diseases 9 (Suppl. 3): S297–S312, 1987
Logan RPH, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, et al. One week eradication regimen for Helicobacter pylori. Lancet 338: 1249–1252, 1991
Lynch W, Davey P, Malek M, Byrne DJ, Napier A. Cost—effectiveness—analysis of the use of chlorhexidine detergent in whole body disinfection in wound infection prophylaxis. Journal of Hospital Infection, in press, 1992
Mackenbach JP, Looman CWN. Secular trends of infectious disease mortality in the Netherlands, 1911–1978: quantitative estimates of changes coinciding with the introduction of antibiotics. International Journal of Epidemiology 17: 618–624, 1988
Mackenzie A, Barnes G. Randomised controlled trial comparing oral and intravenous rehydration therapy in children with diarrhoea. British Medical Journal 303: 393–396, 1991
Malek M, Lynch W, Wells N, Elliott T, Bint A, et al. A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. Journal of Antimicrobial Chemotherapy 29: 207–217, 1992
Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ. Efficacy of amoxicillin with and without decongestant—antihistamine for otitis media with effusion in children: results of a double—blind, randomized trial. New England Journal of Medicine 316: 432–437, 1987
Manning PR, Lee PV, Clintworth WA, Denson TA, Oppenheimer PR, et al. Changing prescribing practices through individual continuing education. Journal of the American Medical Association 256: 230–232, 1986
Maple PAC, Hamilton-Miller JMT, Brumfitt W. World—wide antibiotic resistance in methicillin—resistant Staphylococcus aureus. Lancet 1: 537–540, 1989
Marsh GTN. ‘Curing’ minor illness in general practice. British Medical Journal 2: 1267–1269, 1977
Maung UK, Bolin TD, Duncombe VM, Pereira SP, Khin M, et al. Effect of short—term intermittent antibiotic treatment on growth of Burmese (Myanmar) village children. Lancet 336: 1090–1093, 1990
Mc Farland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile associated diarrhea in a cohort of hospitalized patients. Journal of Infectious Diseases 162: 678–684, 1990
McPherson K. Why do variations occur? In Andersen TF & Mooney G (Eds) The chaIlenges of medical practice variations, pp. 16–35, Macmillan Press, Basingstoke, Hampshire, 1990
Moffatt M, Embree J, Grimm P, Law B. Short—course antibiotic therapy for urinary tract infections in children. American Journal of Diseases of Childhood 142: 57–61, 1988
Molla AM, Molla A, Nath SK, Khatun M. Food—based oral rehydration salt solution for acute childhood diarrhoea. Lancet 2: 429–431, 1989
Moller JK. Antimicrobial usage and microbial resistance in a university hospital during a seven year period. Journal of Antimicrobial Chemotherapy 24: 983–992, 1989
Montefiore D, Rotimi VO, Adeyemi-Doro FAB. The problem of bacterial resistance to antibiotics among strains isolated from hospital patients in Lagos and Ibadan, Nigeria. Journal of Antimicrobial Chemotherapy 23: 641–651, 1989
Mosdell DM, Morrid DM, Voltura A, Pitcher DE, Twiest MW, et al. Antibiotic treatment for surgical peritonitis. Annals of Surgery 214: 543–549, 1991
Moss F, Mc Nicol MW, Mc Swiggan DA, Miller DL. Survey of antibiotic prescribing in a district general hospital. I: pattern of use. Lancet 2: 349–352, 1981a
Moss F, Mc Nicol MW, Mc Swiggan DA, Miller DL. Survey of antibiotic prescribing in a district general hospital. II: lower respiratory tract infection. Lancet 2: 407–409, 1981c
Moss F, Mc Nicol MW, Mc Swiggan DA, Miller DL. Survey of antibiotic prescribing in a district general hospital. III: urinary tract infection. Lancet 2: 461–462, 1981b
Mouton RP, Hermans J, Simoons-Smit AM, Hoogkamp-Korstanje JAA, Degener JE, et al. Correlations between consumption of antibiotics and methicillin resistance in coagulase negative staphylococci. Journal of Antimicrobial Chemotherapy 26: 573–583, 1990
Moxon ER. Modem vaccines: the scope of immunisation. Lancet 335: 448–451, 1990
Moxon ER, Rappuoli R. Modem vaccines: Haemophilus influenzae infections and whooping cough. Lancet 335: 1324–1329, 1990
Mugford M, Banfield P, O’Hanlon M. Effects of feedback of information on clinical practice: a review. British Medical Journal 303: 398–402, 1991
Mulley AG. Medical decision making and practice variation. In Andersen TF & Mooney G (Eds) The challenges of medical practice variations, pp. 59–75, Macmillan Press, Basingstoke, 1990
Munoz R, Coffey TJ, Daniels M, Dowson CG, Laible G, et al. Intercontinental spread of multiresistant clone of serotype 23F Streptococcus pneumoniae. Journal ofinfectious Diseases 164: 302–306, 1991
Nettleman MD, Smith V, Moyer NP. Penicillin resistant Neisseria gonorrhoeae in low prevalence areas: implications for cost—effective management. Sexually Transmitted Diseases 17: 175–180, 1990
Newhouse JG, Paul VM, Waugh NA, Frye CB. Reducing iv waste to under 2.25%. Hospital Pharmacy 23: 241–247, 1988
NIH Task Forces on Antibiotic Use and Antibiotic Resistance Worldwide. Reports of the NIH Task Forces on Antibiotic Use and Antibiotic Resistance Worldwide, pp. S1–S316, Infectious Diseases Society of America, Washington, 1987
Nolan T, Lubitz L, Oberklaid F. Single dose trimethoprim for urinary tract infection. Archives of Diseases of Childhood 64: 581–586, 1989
Normand E. Economics, health, and the economics of health. British Medical Journal 303: 1572–1577, 1991
O’Brien TF. Global surveillance of antibiotic resistance. New England Journal of Medicine 326: 339–340, 1992
O’Brien TF, Members of Task Force 2. Resistance of bacteria to antibacterial agents: report of Task Force 2. Reviews ofinfectious Diseases 9 (Suppl. 3): S244–S260, 1987
O’Hanley P, Easaw J, Rugo H, Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. American Journal of Medicine 87: 605–613, 1989
Obaseiki-Ebor EE, Akerele JO, Ebea PO. A survey of antibiotic outpatient prescribing and antibiotic self—medication. Journal of Antimicrobial Chemotherapy 20: 759–763, 1987
Odio A. The treatment of streptococcal pharyngitis. Journal of the American Medical Association 257: 186, 1987
Pandey RM, Daulaire NM, Starbuck ES, Houston RM, Mc Pherson K. Reduction in total under—five mortality in western Nepal through community—based antimicrobial treatment of pneumonia. Lancet 338: 993–997, 1991
Parker SE, Davey PG. Pharmacoeconomics of intravenous drug administration. PharmacoEconomics 2: 103–115, 1992
Patriarca PA, Arden NH, Koplan JP, Goodman RA. Prevention and control of Type A influenza infections in nursing homes: benefits and costs of four approaches using vaccination and amantadine. Annals ofinternal Medicine 107: 732–740, 1987
Patton JP, Nash DB, Abrutyn E. Urinary tract infection: economic considerations. Medical Clinics of North America 75: 495–513, 1991
Phillips RS, Safran C, Aronson MD, Taylor WE. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal. American Journal of Medicine 86: 297–302, 1989
Pichichero ME, Disney FA, Talpey WB. Adverse and beneficial effects of immediate treatment of Group A beta—haemolytic streptococcal pharyngitis with penicillin. Pediatric Infectious Diseases Journal 6: 635–643, 1987
Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of Group A beta—hemolytic streptococcal pharyngitis: a meta—analysis supporting the concept of microbial cophathogenicity. Pediatric Infectious Diseases Journal 10: 275–281, 1991
Piddock UV, Wray C, Mc Claren I, Wise R. Quinolone resistance in Salmonella spp: veterinary pointers. Lancet 336: 125, 1990
Pitts J, Vincent S. Diagnostic labels, treatment and outcome in acute sore throat. Practitioner 232: 343–346, 1988
Pitts J, Vincent S. What influences doctors’ prescribing? Sore throats revisited. Journal of the Royal College of General Practitioners 39: 65–66, 1989
Platt R, Polk BF, Murdock B, Rosner B. Prevention of catheterassociated urinary tract infection: a cost—benefit analysis. Infection Control and Hospital Epidemiology 10: 60–64, 1989
Plumridge RJ. Cost comparison of intravenous antibiotic administration. Medical Journal of Australia 153: 516–518, 1990
Ponnighaus JM, Fine PEM, Sterne JAC, Wilson RJ, Msosa E, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339: 636–640, 1992
Powers T, Bingham DH. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. American Journal of Hospital Pharmacy 47: 1781–1784, 1990
Quintilliani R, Cooper BW, Briceland L, Nightingale CH. Economic impact of streamlining antibiotic administration. American Journal of Medicine 82 (Suppl. 4a): 391–394, 1987
Reid TMS. The treatment of non-typhi salmonellosis. Journal of Antimicrobial Chemotherapy 29: 4–8, 1992
Rennie D. The Cantekin affair. Journal of the American Medical Association 266: 3333–3337, 1991
Reves RR, Johnson PC, Ericcson CD, Du Pont HL. A cost—effectiveness comparison of the use of antimicrobial agents for treatment or prophylaxis of travelers’ diarrhea. Archives of Internal Medicine 148: 2421–2427, 1988
Rickwood AMK, Carty HM, McKendrick T, Williams MPL, Jackson M, et al. Current imaging of childhood urinary infections: prospective survey. British Medical Journal 304: 663–666, 1992
Ringertz S, Kronvall G. Increased use of erythromycin causes resistance in Haemophilus influenzae. Scandinavian Journal of infectious Diseases 19: 247–256, 1987
Roach AC, Kernodle DS, Kaiser AB. Selecting cost—effective antimicrobial prophylaxis in surgery: are we getting what we pay for? Drug Intelligence and Clinical Pharmacy 24: 183–185, 1990
Robbins A. Modem vaccines: progress towards vaccines we need and do not have. Lancet 335: 1436–1439, 1990
Roos K, Grahn E, Holm SE. Evaluation of beta—lactamase activity and microbiological interference in treatment failures of acute streptococcal tonsillitis. Scandinavian Journal of Infectious Diseases 18: 313–319, 1986
Rubinstein E, Barzilai A, Segev S, Samra Y, Modan M, et al. Antibiotic cost reduction by providing cost information. European Journal of Clinical Pharmacology 35: 269–272, 1988
Sanders CC, Sanders WE, Harrowe DJ. Bacterial interference: Effects of oral antibiotics on the normal throat flora and its ability to interfere with group A streptococci. Infection and Immunity 13: 808–812, 1976
Sanders CC, Nelson GE, Sanders WE. Bacterial interference IV. Epidemiological determinants of the antagonistic activity of the normal throat flora against group A streptococci. Infection and Immunity 16: 599–603, 1977
Sansonetti PJ. Escherichia coli, Shigella, antibiotic—associated diarrhea and prevention and treatment of gastroenteritis. Current Opinion in Infectious Diseases 5: 66–73, 1992
Schaffner W, Ray WA, Federspiel C, Miller WO. Improving antibiotic prescribing in office practice: a controlled trial of three educational methods. Journal of the American Medical Association 250: 1728–1732, 1983
Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost—effectiveness of monoclonal HA—IA antibody for gram—negative sepsis; economic assessment of a new therapeutic agent. Journal of the American Medical Association 266: 3466–3471, 1991
Schultz R, Read AW, Straton JAY, Stanley FJ, Morich P. Genitourinary tract infections in pregnancy and low birth weight: case—control study in Australian Aboriginal women. British Medical Journal 303: 1369–1373, 1991
Selwyn S. Hospital infection: the first 2500 years. Journal of Hospital Infection 18 (Suppl. A): 5–64, 1991
Shann F. Modem vaccines: pneumococcus and influenza. Lancet 335: 898–901, 1990
Simon HJ, Folb PI, Rocha H. Policies, laws and regulations pertaining to antibiotics: Report of Task Force 3. Reviews of Infectious Diseases 9 (Suppl. 3): S261–S269, 1987
Skrabanek P. Nonsensus consensus. Lancet 335: 1446–1447, 1990
Slater AJ. Antibiotic resistance in the tropics 3. Medical responsibilities of the pharmaceutical industry with respect to use of antibiotics in the tropics. Transactions of the Royal Society of Tropical Medicine and Hygiene 83: 45–48, 1989
Smith R. Where is the wisdom? The poverty of medical evidence. British Medical Journal 303: 798–799, 1991
Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co—trimoxazole with chloramphenicol plus doxycycline and co—trimoxazole for treatment of severe melioidosis. Antimicrobial Agents and Chemotherapy 36: 158–162, 1992
St Leger AS, Schnieden H, Walsworth-Bell JP. Evaluating health services’ effectiveness, pp. 1–212, Open University Press, Buckingham, 1992
Stanford JL, Grange JM, Pozniak A. Is Africa lost? Lancet 338: 557–558, 1991
Stott NHC. Management and outcome of winter upper respiratory tract infections in children aged 0–9 years. British Medical Journal 1: 29–31, 1979
Sturm AW. Effects of a restrictive antibiotic policy on clinical efficacy of antibiotics and susceptibility patterns of organisms. European Journal of Clinical Microbiology and Infectious Diseases 9: 381–389, 1990
Sugarman B, Young EJ. Infections associated with prosthetic devices: magnitude of the problem. Infectious Diseases Clinics of North America 3: 187–196, 1989
Sutrisna B, Frerichs RR, Reingold AL. Randomised, controlled trial of effectiveness of ampicillin in mild acute respiratory infections in Indonesian children. Lancet 338: 471–474, 1991
Sutters CA. Peer group review of drugs — the way forward. Pharmaceutical Journal 246–248, 1989
Swindell PJ, Reeves DS, Bullock DW, Davies AJ, Spence CE. Audits of antibiotic prescribing in a Bristol hospital. British Medical Journal 286: 118–122, 1983
Taboulet F. Presentation d’une methodologie pennettant de mesurer en quantite et de com parer les consommations pharmaceutiques. Journal d’Economie Medicale 8: 37–63, 1990
Taylor D. Prescribing in Europe — forces for change. British Medical Journal 304: 239–242, 1992
Taylor G, McKenzie M, Kirkland T, Wiens R. Effect of surgeon’s iagnosis on surgical wound infection rates. American Journal of infection Control 18: 295–299, 1990
Thamlakitkul V. Antibiotic dispensing by drug store personnel in Bangkok, Thailand. Journal of Antimicrobial Chemotherapy 21: 125–131, 1988
Trienekens TAM, Stobberingh EE, Winkens RAG, Houben AW. Different lengths of treatment with co—trimoxazole for acute uncomplicated urinary tract infections in women. British Medical Journal 299: 1319–1322, 1989
Urbina R, Prado V, Canelo E. Trimethoprim resistance in enterobacteria in Chile. Journal of Antimicrobial Chemotherapy 23: 143–149, 1989
Van Buchen FL, Dunk JHM, Van’t Hof MA. Therapy of acute otitis media: myringotomy, antibiotics or neither? A double blind study in children. Lancet 2: 883–886, 1981
Vandenbroucke-Grauls CJE, Vandenbroucke JP. Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 338: 859–862, 1991
Verma BL, Srivastava RN. Measurement of the personal cost of illness due to some major water—related diseases in an Indian rural population. International Journal of Epidemiology 19: 169–176, 1990
Viladrich PF, Gudiol F, Linares J, Pallares R, Sabate I, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 35: 2467–2472, 1991
Vogels MTE, van der Meer JWM. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrobial Agents and Chemotherapy 36: 1–5, 1992
Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin—clavulanate potassium in acute paranasal sinus infections in children: a double—blind, placebo—controlled trial. Pediatrics 77: 795–800, 1986
Walsh BT, Bookheim WW, Johnson RC. Recognition of streptococcal pharyngitis in adults. Archives of Internal Medicine 135: 1493–1497, 1975
Warren HS, Danner RL, Munford RS. Anti—endotoxin monoclonal antibodies. New England Journal of Medicine 326: 1153–1157, 1992
Washington AE, Browner WS, Korenbrot CC. Cost—effectiveness of combined treatment for endocervical gonorrhea. Journal of the American Medical Association 257: 2056–2060, 1987
Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New England Journal of Medicine 325: 81–86, 1991
Wenzel RP. Anti—endotoxin antibodies — a second look. New England Journal of Medicine 326: 1151–1153, 1992
Zenilman JM. Epidemiology and control of sexually transmitted diseases. Current Opinion in Infectious Diseases 5: 36–43, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davey, P.G., Malek, M.M. & Parker, S.E. Pharmacoeconomics of Antibacterial Treatment. Pharmacoeconomics 1, 409–437 (1992). https://doi.org/10.2165/00019053-199201060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199201060-00003